Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma

Cancer

Volumn 80, Issue 9, 1997, Pages 1755-1759

  Small, Eric J ^a,b   Baron, Ari ^a   Bok, Robert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiandrogen withdrawal; Hormone refractory prostate carcinoma; Ketoconazole; Prostate specific antigen

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; HYDROCORTISONE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; FATIGUE; HUMAN; LIVER TOXICITY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SKIN TOXICITY; VOMITING;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COHORT STUDIES; FLUTAMIDE; HUMANS; HYDROCORTISONE; KETOCONAZOLE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0030695382     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1755::AID-CNCR9>3.0.CO;2-D     Document Type: Article

References (12)

1. Small EJ, Srinivas S. The anti-androgen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Cancer 1995;76:1428-34.
2. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 1993;11:1566-72.
3. Small EJ, Carroll PR. Prostate specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994;43:408-10.
4. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the anti-androgen withdrawal syndrome. J Urol 1995;153:1946-7.
5. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8.
6. Small EJ, Vogelzang NJ. Second line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15:382-8.
7. Small EJ, Baron A, Fippin L, Apodaca D. Ketoconazole retains activity in "hormone refractory" prostate cancer. J Urol 1997;157:1204-7.
8. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of hormone refractory prostate cancer. J Natl Cancer Inst 1994;86:222-7.
9. Kelley WK, Curley T, Leibertz C. Prospective evaluation of hyrdocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13:2208-13.
10. Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet 1984;2:433-5.
11. Tapazoglou E, Subramanian MG, Al-Sarraf M. High-dose ketoconazole therapy in patients with metastatic prostate cancer. Am J Clin Oncol 1986;9:369-75.
12. Williams G, Kerle DJ, Ware H. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 1986;58:45-51.